Blog
- Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials
- Liposomes vs. Lipid Nanoparticles: Which Is Best for Drug Delivery?
- BCMA/CD3 Bispecific Antibodies for Multiple Myeloma (MM)
- ADC Drugs: Some Challenges To Be Solved
- ROR1 ADCs in Clinical Trials: MK-2140, NBE-002 & CS5001
- Claudin6 (CLDN6): A Emerging Target For Solid Tumor
- Alzheimer's Disease Drug Development: Aducanumab, Lecanemab & Donanemab
- Trophoblast Glycoprotein (TPGB/5T4): A New Target For ADC Drugs
- Summary of ADC Targets For Solid Tumors & Hematological Tumors
- PEG‐rhG‐CSF for Neutropenia